This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine and docetaxel: Interim study results No significant financial ...

NEW YORK--(BUSINESS WIRE)--Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced the availability of Mindpeak’s AI algorithms for IHC biomarker ...

Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non–small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 ...

A proof of concept study suggests an FT-IR microspectroscopy blood test can detect a single circulating tumour cell in a lung cancer patient, supporting future real time monitoring.

As the First Laboratory to Validate Ki-67 IHC MIB-1 pharmDx (Dako Omnis), Quest Plans to Make Testing Available Nationally by the End of October SECAUCUS, N.J., Oct. 18, 2021 /PRNewswire/ -- Quest ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...